Short-term azithromycin use is associated with QTc interval prolongation in children with cystic fibrosis

Basit Öğe Kaydı
dc.contributor.authorEnhoş, A.
dc.contributor.authorDoğuş, Kus, H.
dc.contributor.authorYozgat, C.Y.
dc.contributor.authorCakır, E.
dc.contributor.authorYazan, H.
dc.contributor.authorErol, A.B.
dc.contributor.authorErenberk U.
dc.date.accessioned2024-05-19T14:33:24Z
dc.date.available2024-05-19T14:33:24Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: Azithromycin is used for children with cystic fibrosis (CF) for its immunomodulatory and anti-inflammatory action. This study investigated the short-term alterations in QTc interval associated with azithromycin prophylaxis in pediatric patients with CF. Methods: This study included 121 patients with mild CF, of whom 76 received azithromycin (patient group) and 45 did not receive azithromycin (control group). The patient and control groups were categorized according to age as under 12 years of age and over 12 years of age. The first presentation measured all the patient and control groups at basic QTc time intervals. The QTc intervals of all patients were then remeasured systemically at 1, 3, and 6 months. Age categories and QTc intervals that were calculated at each month in the patient and control groups were compared statistically. Results: A statistically significant difference was detected in the patient group between the initial QTc interval time and the electrocardiogram (ECG) findings in the first and third months after prophylaxis treatment (p < 0.001; p = 0.01). However, no statistically significant difference was detected in the sixth month (p > 0.05) in all groups. Almost all of the children's QTc intervals were within normal range and within the safety zone (under 0.44 s). No statistically significant difference was detected in the control group between the initial ECG and the QTc intervals measured at 1, 3, and 6 months. Conclusion: Short-term use of azithromycin prophylaxis in pediatric patients with mild CF slightly increased the QTc interval in the first and third months of follow-up. Nevertheless, all QTc interval changes fell within the safety zone. Notably, 1 month of follow-up treatment should be performed to check for any alteration in the QTc interval. If increased QTc interval duration is not detected in the first month, azithromycin prophylaxis can be safely prescribed. © 2024 French Society of Pediatricsen_US
dc.identifier.doi10.1016/j.arcped.2024.02.004
dc.identifier.issn0929-693X
dc.identifier.scopus2-s2.0-85190719976en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1016/j.arcped.2024.02.004
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4220
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Masson s.r.l.en_US
dc.relation.ispartofArchives de Pediatrieen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAzithromycin Prophylaxisen_US
dc.subjectChildhooden_US
dc.subjectChronic Lung Diseaseen_US
dc.subjectQtc Prolongationen_US
dc.titleShort-term azithromycin use is associated with QTc interval prolongation in children with cystic fibrosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu